Cargando…

Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study

BACKGROUND: Herpes zoster (HZ) is a painful condition that can have a substantial negative impact on patients’ lives. However, UK-specific data on the debilitating impact of HZ, in terms of patients’ experience of pain and impairments in Health-Related Quality of Life (HRQoL) are limited. The Zoster...

Descripción completa

Detalles Bibliográficos
Autores principales: Gater, Adam, Abetz-Webb, Linda, Carroll, Stuart, Mannan, Azharul, Serpell, Mick, Johnson, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223600/
https://www.ncbi.nlm.nih.gov/pubmed/25038799
http://dx.doi.org/10.1186/1471-2334-14-402
_version_ 1782343227014119424
author Gater, Adam
Abetz-Webb, Linda
Carroll, Stuart
Mannan, Azharul
Serpell, Mick
Johnson, Robert
author_facet Gater, Adam
Abetz-Webb, Linda
Carroll, Stuart
Mannan, Azharul
Serpell, Mick
Johnson, Robert
author_sort Gater, Adam
collection PubMed
description BACKGROUND: Herpes zoster (HZ) is a painful condition that can have a substantial negative impact on patients’ lives. However, UK-specific data on the debilitating impact of HZ, in terms of patients’ experience of pain and impairments in Health-Related Quality of Life (HRQoL) are limited. The Zoster Quality of Life (ZQOL) study, a large-scale UK cross-sectional study, was conducted to quantify the burden of HZ in UK patients. METHODS: A total of 229 HZ patients aged 50 years or over were recruited from primary and secondary/tertiary care centres throughout the UK. Patients completed a battery of validated questionnaires, including the Zoster Brief Pain Inventory (ZBPI), the Medical Outcomes Study Short-Form 36 (SF-36) and the EuroQol-5 Dimensions (EQ-5D) on initial presentation to the doctor and again 7–14 days later. At follow-up patients also completed the Treatment Satisfaction with Medication (TSQM) questionnaire. Where available, mean questionnaire scores in the HZ population were compared to scores for age-matched norms to investigate the burden associated with HZ. RESULTS: Pain was prominent among patients, with 57.9% at the initial study visit reporting pain in the preceding 24 hours at levels typically considered to have a significant impact on HRQoL (i.e. ZBPI worst pain ≥ 5). This was reflected in SF-36 and EQ-5D scores that were significantly lower for patients when compared to age-matched norms (p < 0.05) - except for the SF-36 domain of physical functioning. HRQoL was inversely associated with levels of reported pain, with those patients in the greatest amount of pain reporting the greatest HRQoL impact. However, there was no association between pain severity and participant age. The majority of patients (69.4%) received antivirals within 72 hours of rash appearing and 69.9% of patients were also taking analgesics for the management of HZ pain. TSQM scores indicated that patients were least satisfied with the effectiveness of their prescribed treatment. CONCLUSIONS: The acute presentation of HZ is a painful experience that can have a significant impact on the physical and mental wellbeing of sufferers. Findings highlight significant unmet need among patients, particularly in terms of the effectiveness of therapies for the management of HZ.
format Online
Article
Text
id pubmed-4223600
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42236002014-11-08 Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study Gater, Adam Abetz-Webb, Linda Carroll, Stuart Mannan, Azharul Serpell, Mick Johnson, Robert BMC Infect Dis Research Article BACKGROUND: Herpes zoster (HZ) is a painful condition that can have a substantial negative impact on patients’ lives. However, UK-specific data on the debilitating impact of HZ, in terms of patients’ experience of pain and impairments in Health-Related Quality of Life (HRQoL) are limited. The Zoster Quality of Life (ZQOL) study, a large-scale UK cross-sectional study, was conducted to quantify the burden of HZ in UK patients. METHODS: A total of 229 HZ patients aged 50 years or over were recruited from primary and secondary/tertiary care centres throughout the UK. Patients completed a battery of validated questionnaires, including the Zoster Brief Pain Inventory (ZBPI), the Medical Outcomes Study Short-Form 36 (SF-36) and the EuroQol-5 Dimensions (EQ-5D) on initial presentation to the doctor and again 7–14 days later. At follow-up patients also completed the Treatment Satisfaction with Medication (TSQM) questionnaire. Where available, mean questionnaire scores in the HZ population were compared to scores for age-matched norms to investigate the burden associated with HZ. RESULTS: Pain was prominent among patients, with 57.9% at the initial study visit reporting pain in the preceding 24 hours at levels typically considered to have a significant impact on HRQoL (i.e. ZBPI worst pain ≥ 5). This was reflected in SF-36 and EQ-5D scores that were significantly lower for patients when compared to age-matched norms (p < 0.05) - except for the SF-36 domain of physical functioning. HRQoL was inversely associated with levels of reported pain, with those patients in the greatest amount of pain reporting the greatest HRQoL impact. However, there was no association between pain severity and participant age. The majority of patients (69.4%) received antivirals within 72 hours of rash appearing and 69.9% of patients were also taking analgesics for the management of HZ pain. TSQM scores indicated that patients were least satisfied with the effectiveness of their prescribed treatment. CONCLUSIONS: The acute presentation of HZ is a painful experience that can have a significant impact on the physical and mental wellbeing of sufferers. Findings highlight significant unmet need among patients, particularly in terms of the effectiveness of therapies for the management of HZ. BioMed Central 2014-07-20 /pmc/articles/PMC4223600/ /pubmed/25038799 http://dx.doi.org/10.1186/1471-2334-14-402 Text en Copyright © 2014 Gater et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gater, Adam
Abetz-Webb, Linda
Carroll, Stuart
Mannan, Azharul
Serpell, Mick
Johnson, Robert
Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study
title Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study
title_full Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study
title_fullStr Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study
title_full_unstemmed Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study
title_short Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study
title_sort burden of herpes zoster in the uk: findings from the zoster quality of life (zqol) study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223600/
https://www.ncbi.nlm.nih.gov/pubmed/25038799
http://dx.doi.org/10.1186/1471-2334-14-402
work_keys_str_mv AT gateradam burdenofherpeszosterintheukfindingsfromthezosterqualityoflifezqolstudy
AT abetzwebblinda burdenofherpeszosterintheukfindingsfromthezosterqualityoflifezqolstudy
AT carrollstuart burdenofherpeszosterintheukfindingsfromthezosterqualityoflifezqolstudy
AT mannanazharul burdenofherpeszosterintheukfindingsfromthezosterqualityoflifezqolstudy
AT serpellmick burdenofherpeszosterintheukfindingsfromthezosterqualityoflifezqolstudy
AT johnsonrobert burdenofherpeszosterintheukfindingsfromthezosterqualityoflifezqolstudy